How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

550 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

461. Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

in greater than physiologic doses) in the 4 weeks prior to baseline. G-CSF and epoietin use are permitted. Anti-HBV therapy other than lamivudine (such as emtricitabine, lobucavir, entecavir, HBIG, clevudine, MCC-478) with the exception of interferon alpha, famciclovir or foscarnet that ended more than 12 weeks prior to screen. Hepatic mass suggestive of hepatocellular carcinoma Alpha-fetoprotein level greater than or equal to 200ng/mL Evidence of gastrointestinal malabsorption or chronic nausea

2001 Clinical Trials

462. A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients

anti-HSV therapy, which is defined as therapy of 12 or more weeks.) Agree to use effective methods of birth control from 2 weeks before taking study drug, throughout the study, and for 4 weeks after completing the study. (A female may be eligible if not able to have children.) Exclusion Criteria Patients will not be eligible for this study if they: Have blood vessel disease. Are sensitive to acyclovir, Valtrex, famciclovir, or ganciclovir. Are unable to take medications by mouth. Have non-healed (...) to acyclovir, Valtrex, famciclovir, or ganciclovir. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005663 Sponsors and Collaborators Glaxo Wellcome More Information Go to Layout table for additonal information ClinicalTrials.gov Identifier: Other Study

2000 Clinical Trials

463. Valaciclovir to Prevent Transmission of Herpes Simplex Virus

transaminase (ALT) level greater than 3 times the normal upper limit. Known resistance to aciclovir, famciclovir, or ganciclovir. Known hypersensitivity to aciclovir, valaciclovir, famciclovir, or ganciclovir. Malabsorption syndrome or other gastrointestinal dysfunction that might impair drug dynamics. Subjects known to be lactose intolerant. Women contemplating pregnancy within the duration of study drug dosing for this study. Women of child bearing potential not using an effective method of contraception

1999 Clinical Trials

464. A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

group A Streptococcus with symptoms of streptococcal pharyngitis, a positive culture from a normally sterile site, or symptoms of bacterial pneumonia. Are HIV positive. Have cancer. Have had any period of irregular heartbeat. Have had chemotherapy or other drugs that suppress the immune system within 30 days. Have taken by mouth or injection any antiviral drug (other than acyclovir, famciclovir, amantadine or rimantadine.) Have taken by mouth or injection corticosteroids equivalent to approximately

2000 Clinical Trials

465. The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood

: Documented or suspected HSV within 2 months prior to study entry. History of infection with an acyclovir resistant HSV strain. History of disseminated HSV. History of treatment for acute CMV or MAC disease. History of poor medication or clinic visit compliance. Prior Medication: Excluded: Use of acyclovir, famciclovir, foscarnet, ganciclovir, valacyclovir or cidofovir for any reason within one month prior to study entry. [AS PER AMENDMENT 1/21/97: Use of antiherpes agents, both FDA-approved

1999 Clinical Trials

466. The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients

: Patients with the following symptoms and conditions are excluded: Evidence of active CMV disease at screening. Conditions that would require use of medications listed in Exclusion Concurrent Medications. Concurrent Medication: Excluded: Any investigational anti-CMV agent. Adenine arabinoside (vidarabine). Amantadine hydrochloride (Symmetrel). Cidofovir (Vistide). CMV hyperimmune globulin. Cytosine arabinoside (cytarabine). Famciclovir. Foscarnet (phosphonoformic acid). Ganciclovir (Cytovene). GW (...) 1263W94 (Benzamidazole). Idoxuridine. Intravenous acyclovir. ISIS 2922 (Anti-sense). Lobucavir. MSL109. Oral acyclovir > 1 g/day. Valacyclovir. Patients with the following prior conditions are excluded: History of CMV end-organ disease. Prior Medication: Excluded within 2 weeks of randomization: Any investigational anti-CMV agent. Adenine arabinoside (vidarabine). Amantadine hydrochloride (Symmetrel). Cidofovir (Vistide). CMV hyperimmune globulin. Cytosine arabinoside (cytarabine). Famciclovir

1999 Clinical Trials

467. Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver

antiviral agent active against herpes simplex virus (e.g., acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, foscarnet, or cidofovir) during and for 28 days after study therapy No concurrent immunosuppressive agents (e.g., cyclosporine) during and for 28 days after study therapy No other concurrent investigational or anti-cancer agents during and for 28 days after study therapy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study

2001 Clinical Trials

468. Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

within 1 month prior to baseline Treatment with immunomodulator drugs (interleukins, corticosteriods for indications other than the treatment of adrenal insufficiency) in the 4 weeks prior to baseline. G-CSF and epoetin use are permitted. Anti-HBV therapy other than lamivudine (such as emtricitabine, lobucavir, entecavir, HBIG, clevudine, MCC-478) with the exception of interferon alpha, famciclovir or foscarnet that ended more than 12 weeks prior to screen. Hepatic mass suggestive of hepatocellular

2001 Clinical Trials

469. The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children

HSV or VZV, such as acyclovir, famciclovir, ganciclovir, foscarnet, and sorivudine. Probenecid. Aspartamine within 48 hours prior to pharmacokinetic samplings. Patients with the following prior conditions are excluded: Grade 2 creatinine value within the past 30 days. Grade 3 hematologic or hepatic values within the past 30 days. Prior hypersensitivity and/or allergic reaction to acyclovir. Grade 3 or 4 mental status changes within the past 30 days. Prior Medication: Excluded: Acyclovir within 1

1999 Clinical Trials

470. Antiviral drugs in chronic hepatitis B: review and meta-analysis. (PubMed)

though combination therapy with cortisone seemed to achieve very good results (remission rates ranging from 45% to 66% in patients treated). Lamivudine did not seem to furnish lasting effects in chronic hepatitis B, because many patients relapse after suspension of the treatment due to the appearance of HBV variants resistant to the drug. Contrasting results were observed with famciclovir. Treatment of chronic hepatitis B, with this drug seemed capable of reducing HBV-DNA serum levels by a mean of 50

2001 International journal of clinical pharmacology and therapeutics

471. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. (PubMed)

are described who developed hepatitis B reactivation and liver decompensation after stopping therapy. One of the three patients was participating in a famciclovir trial and the other two were receiving lamivudine therapy for active hepatitis B infection. All three patients had documented hepatitis B flares, and all had hepatitis B virus DNA detected at that time. All patients developed decompensated liver disease despite one patient having had a prior liver biopsy showing absence of cirrhosis

Full Text available with Trip Pro

2002 Gut

472. Treatment of recurrent hepatitis B infection in liver transplant recipients. (PubMed)

of therapy, is its main limitation. 3. Famciclovir is safe in liver transplant recipients; however, virological and clinical responses are less consistent than with lamivudine. Thus, lamivudine is favored over famciclovir as first-line therapy in transplant recipients with no previous exposure to nucleoside analogues. 4. Although limited in availability, adefovir dipivoxil appears safe and effective in treating liver transplant recipients with lamivudine-resistant HBV disease. Close monitoring of renal (...) function is recommended, with dose adjustment in patients with reduced creatinine clearances. 5. Limited data suggest that intravenous ganciclovir, tenofovir disoproxil fumarate, and interferon alfa may be useful as rescue therapies for patients with lamivudine- or famciclovir-resistant HBV disease. 6. Antiviral therapy with two or more suitable agents may minimize the chance for viral resistance; therefore, future therapeutic strategies likely will use combination therapy in the long-term management

Full Text available with Trip Pro

2002 Liver Transplantation

473. Challenges in genital herpes simplex virus management. (PubMed)

acyclovir, famciclovir, and valacyclovir, treatment of mucocutaneous HSV is a practice of everyday medical care. Yet, despite effective drugs, there is widespread discontent by clients and providers about care of patients with genital herpes. Much of this relates to transmission complexities and the varied natural history of the infection. However, over time, most patients adjust to their disease and the medical and psychosocial complications. Recent studies show condoms reduce transmission, providing

Full Text available with Trip Pro

2002 Journal of Infectious Diseases

474. Progress in meeting today's demands in genital herpes: an overview of current management. (PubMed)

simplex infection are common and patient education is essential. Patient concerns extend beyond disease frequency and severity-the psychological impact should not be underestimated. Antiviral therapy is relevant at all stages of infection. Acyclovir, valacyclovir, and famciclovir are effective and well tolerated for genital herpes treatment. Continuous suppressive therapy controls all symptoms of recurrent disease and helps to relieve disease complications. The prodrugs valacyclovir and famciclovir

Full Text available with Trip Pro

2002 Journal of Infectious Diseases

475. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. (PubMed)

were similar to the effects on viral DNA replication. These data suggest that penciclovir or its oral form, famciclovir, may have clinical utility in the treatment of chronic hepatitis B virus infection.

Full Text available with Trip Pro

1994 Antimicrobial Agents and Chemotherapy

476. Dilemmas in care of the elderly. (PubMed)

Dilemmas in care of the elderly. 9426930 1998 01 30 2018 12 01 0008-350X 43 1997 Dec Canadian family physician Medecin de famille canadien Can Fam Physician Dilemmas in care of the elderly. 2123 Pereles L L Division of Geriatric Medicine, University of Alberta. Triscott J J Meiring P P eng Case Reports Journal Article Canada Can Fam Physician 0120300 0008-350X 0 Antiviral Agents 0 Prodrugs 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir IM 2-Aminopurine administration & dosage analogs (...) & derivatives economics therapeutic use Age Factors Aged Aged, 80 and over Antiviral Agents administration & dosage economics therapeutic use Costs and Cost Analysis Famciclovir Female Herpes Zoster drug therapy economics physiopathology Humans Middle Aged Pain etiology prevention & control Prodrugs economics Time Factors 1998 1 14 1998 1 14 0 1 1998 1 14 0 0 ppublish 9426930 PMC2255083 BMJ. 1989 Feb 18;298(6671):431 2495051 Hosp Pract (Off Ed). 1990 Oct 30;25(10A):61-71, 75-6 2120265 N Engl J Med. 1994 Mar

Full Text available with Trip Pro

1997 Canadian Family Physician

477. Necrotising herpetic retinopathy in patients with advance HIV disease. (PubMed)

with intravenous aciclovir for 6 weeks: three subsequently received oral famciclovir and one oral valaciclovir; two patients also had intravitreal injections of foscarnet. In none of the four did treatment bring about improvement in visual acuity, but in all four visual loss from retinitis was halted.NHR occurs in HIV infected patients with advanced HIV disease and is strongly associated with evidence of VZV infection. With aggressive use of antiviral drugs the outcome is not uniformly poor.

Full Text available with Trip Pro

1997 Genitourinary Medicine

478. Hepatitis B virus infection and liver transplantation. (PubMed)

Hepatitis B virus infection and liver transplantation. 9203930 1997 07 10 2018 11 30 0017-5749 40 5 1997 May Gut Gut Hepatitis B virus infection and liver transplantation. 568-71 Terrault N A NA Veterans Administration Medical Center, San Francisco, CA 94121, USA. Wright T L TL eng Journal Article England Gut 2985108R 0017-5749 0 Antiviral Agents 0 Hepatitis B Vaccines 0 Immunoglobulins 2T8Q726O95 Lamivudine 452-06-2 2-Aminopurine 82115-62-6 Interferon-gamma QIC03ANI02 Famciclovir XII270YC6M (...) hepatitis B hyperimmune globulin AIM IM X 2-Aminopurine administration & dosage analogs & derivatives Antiviral Agents administration & dosage Famciclovir Hepatitis B etiology prevention & control therapy Hepatitis B Vaccines administration & dosage Humans Immunization, Passive Immunoglobulins administration & dosage Immunosuppression Interferon-gamma administration & dosage Lamivudine administration & dosage Liver Transplantation Patient Selection 1997 5 1 1997 5 1 0 1 1997 5 1 0 0 ppublish 9203930

Full Text available with Trip Pro

1997 Gut

479. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient (PubMed)

failure, and onset of liver dysfunction was observed when resistant virus was the dominant serum species. In three patients, liver recovery was observed when immunosuppression was stopped and when alternative antivirals were given. Wild type virus appeared to respond to ganciclovir, and to reintroduction of lamivudine. For one patient, introduction of famciclovir was associated with clinical, virological, and histological response.Failure of lamivudine prophylaxis may identify patients at special risk

Full Text available with Trip Pro

2000 Gut

480. In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir (PubMed)

against HBV in their respective prodrug forms (famciclovir and adefovir dipivoxil [bis-(POM)-PMEA]). Since multidrug combinations are likely to be used to control HBV infection, investigation of potential interactions between PCV, 3TC, and PMEA is important. Primary duck hepatocyte cultures which were either acutely or congenitally infected with the duck hepatitis B virus (DHBV) were used to investigate in vitro interactions between PCV, 3TC, and PMEA. Here we show that the anti-DHBV effects of all

Full Text available with Trip Pro

2000 Antimicrobial Agents and Chemotherapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>